What Does Danaher (DHR) FDA Clearance For AI AFib Detection Mean Now?
Danaher Posts First Earnings Under New CEO; Emphasizes Need For Improved Execution, Innovation
Citigroup Maintains Buy on Danaher, Raises Price Target to $270
Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
LH vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Q3 Earnings Fuel Stock Gains On Margin Expansion
Barclays Maintains Overweight on Danaher, Raises Price Target to $260
JP Morgan Maintains Overweight on Danaher, Raises Price Target to $270
TD Cowen Maintains Buy on Danaher, Raises Price Target to $270
Stifel Maintains Buy on Danaher, Raises Price Target to $260
DHR Q3 deep dive: execution focus and AI strategy underpin improved outlook
Baird Maintains Outperform on Danaher, Raises Price Target to $254
Danaher (DHR) Stock Fair Value Edges Higher After Analysts Lift Targets
Why Danaher Stock Bounced Higher Today
Danaher Reports Third Quarter 2026 Results
Danaher: 3 Key Takeaways for Long-Term Investors
Danaher (DHR) Q3 2026 Earnings Call Transcript
Danaher Corporation Q3 2026 Earnings Call Summary
Danaher Jumps 4% on Q3 Beat: “Improving Trends” Across Its End Markets
Medical Giants Thermo Fisher, Danaher Reverse Higher — What Investors Are Seeing
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
